A Multinational Study Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN1)

This study is testing a new oral targeted drug called DZD6008 for people with advanced non-small cell lung cancer (NSCLC) that has a specific gene mutation called an EGFR mutation — either as a first treatment or after prior targeted therapy has stopped working. **You may be eligible if...** - You are 18 or older - You have advanced or metastatic non-small cell lung cancer confirmed by biopsy - Your tumor has a confirmed EGFR mutation (such as Exon 19 deletion or L858R) - If previously treated: your prior EGFR-targeted therapy has stopped working or you could not tolerate it - You can provide tumor tissue samples **You may NOT be eligible if...** - Your cancer does not have an EGFR mutation - You have serious organ problems or other major health conditions - You are unable to take oral medication - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.